
Yatharth Q2FY27: consolidated revenue +54% YoY, margin compression caps PAT at +17%
Consolidated revenue for Q2 FY27 rose 54.4% YoY (and 9.9% QoQ) to ₹431.42 Cr, continuing the pace set in Q1 FY27 (+52.3% YoY) and running well ahead of management's guidance to outgrow FY26's 36% full-year growth. Consolidated PAT grew a slower 17.5% YoY to ₹48.46 Cr, with profit attributable to owners at ₹50.59 Cr (EPS ₹5.25, +22.7% YoY) — the gap between the two PAT figures stems from a ₹2.13 Cr quarterly loss at minority-held new-hospital subsidiaries (five such units reported a combined ₹4.19 Cr net loss this quarter per the auditors' note), a loss borne by minority shareholders rather than the parent. Net profit margin compressed to 11.10% from 14.28% a year earlier, even as operating margin (EBITDA/revenue) held roughly flat at 23.65% versus 23.09% YoY — the squeeze sits below the EBITDA line. Finance costs jumped to ₹8.28 Cr from just ₹0.26 Cr a year ago, and depreciation rose 75% YoY to ₹33.14 Cr, both tracking the capex behind new hospitals (consolidated borrowings rose to ₹450.69 Cr from ₹253.33 Cr at FY26-end, with gross block and CWIP at ₹9,513 Cr and ₹2,421 Cr respectively). Management had flagged this dynamic on the prior call: new hospitals are only expected to reach 25-27% EBITDA margins by FY28-29, and this quarter's 23.65% OPM, though better than Q1's 23.35%, still sits under the company's stated ">24%" floor. Against the prior concall's confident, optimistic tone and the guidance to outgrow FY26's 36% revenue growth, this quarter's 54% YoY print clearly beats the topline promise, while the margin commitment is not yet met but is trending the right way sequentially. No Q2 FY27-specific street estimates for this company turned up in a search for brokerage previews, so vsStreet is unknown; FY27 full-year consensus (per analyst trackers) pegs revenue near ₹1,700 Cr (+41% YoY), a bar this quarter's run-rate is tracking ahead of. Standalone PAT was ₹37.06 Cr on standalone revenue of ₹194.91 Cr — under half of consolidated revenue — underscoring that a growing share of both growth and margin drag now sits inside subsidiaries rather than the parent entity. The quarter's biggest non-operating development was the October 15, 2026 EGM approval for Rasmalai Limited, an Advent International affiliate, to acquire a 24.9% stake in the company via preferential issue on a fully diluted basis, pending regulatory approvals. Separately, the company disclosed a ₹29.66 Cr income-tax demand covering AY2014-15 to AY2024-25 as a contingent liability, with no provision made, stating it expects substantial relief on appeal.
Key Highlights
- Consolidated revenue ₹431.42 Cr, up 54.4% YoY and 9.9% QoQ, led by new-hospital ramp-up in the NCR cluster.
- Consolidated PAT ₹48.46 Cr, up 17.5% YoY but trailing revenue growth; profit attributable to owners ₹50.59 Cr (EPS ₹5.25), up 22.7% YoY as minority shareholders absorbed a ₹2.13 Cr subsidiary loss.
- NPM compressed to 11.10% from 14.28% a year ago; OPM roughly flat at 23.65% vs 23.09% YoY, as finance costs rose to ₹8.28 Cr from ₹0.26 Cr and D&A rose 75% YoY to ₹33.14 Cr on new-hospital capex.
- Revenue growth of 54% YoY runs well ahead of management's FY27 target to beat FY26's 36% growth; OPM of 23.65% still trails the >24% guided floor, though improved sequentially from Q1's 23.35%.
- Standalone PAT ₹37.06 Cr on standalone revenue ₹194.91 Cr — under half of consolidated revenue, reflecting how much growth now sits in subsidiaries housing newer hospitals.
- Shareholders approved a preferential issue to Rasmalai Limited (Advent International affiliate) for a 24.9% fully-diluted stake, cleared at the October 15, 2026 EGM, pending regulatory approvals.
- ₹29.66 Cr income-tax demand for AY2014-15 to AY2024-25 disclosed as a contingent liability; company confident of relief on appeal, no provision booked.
Price Impact
More from YATHARTH